Please cite this article in press Dhafer Sawab Dhafer Alshehri et al, An Overview Of Potential Antioxidant Mechanism Of Action For Metronidazole., Indo Am. J. P. Sci, 2022; 09(8).

,

1. Freeman C.D., Klutman N.E., Lamp K.C. Metronidazole. A therapeutic review and update. Drugs. 1997;4:679–708.
2. Ramasubbu D.A., Smith V., Hayden F., Cronin P. Systemic antibiotics for treating malignant wounds. Cochrane Database Syst. Rev. 2017;24:CD011609.
3. Aronson I.K., Rumsfield J.A., West D.P., Alexander J., Fischer J.H., Palouceket F.P. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell. Clin. Pharm. 1987;21:346–351.
4. Hoffmann C., Fock N., Franke G., Zsciesche M., Siegmund W. Comparative bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration. Int. J. Clin. Pharmacol. Ther. 1995;33:232–239.
5. Cosar C., Julou L. Activitiè de1’(hydroxy-2-ethyl)-1-methyl-2-nitro-5-imidazole (8.823R.P.) vis-a-vis des infections expérimentales à Trichomonas vaginalis. Ann. Inst. Pasteur. 1959;96:238–241.
6. World Health Organization Essential drugs. WHO Drug Inf. 1999;13:249–262.
7. Lau A.H., Lam N.P., Piscitelli S.C., Wikes L., Danziger L.H. Clinical pharmakokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 1992;23:328–364.
8. Amon I., Amon K., Hüller H. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int. J. Clin. Pharmacol. 1978;16:384–386.
9. Loft S., Otton S.V., Lennard M.S., Tucker G.T., Poulsen H.E. Characterization of metronidazole metabolism by human liver microsomes. Biochem. Pharmacol. 1991;41:1127–1134.
10. Koch R.L., Beaulieu B.B., Chrystal E.J., Goldman P. A metronidazole metabolite in human urine and its risks. Science. 1981;211:398–400.
11. Müller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery. 1983;93:165–171.
12. Saghaug C.S., Klotz C., Kallio J.P., Brattbakk H.R., Stokowy T., Aebischer T., Kursula I., Langeland N., Hanevik K. Genetic variation in metronidazole metabolism and oxidative stress pathways in clinical Giardia lamblia assemblage A and B isolates. Infect. Drug Resist. 2019;12:1221–1235.
13. Löfmark S., Elund C., Nord C.E. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 2010;50(Suppl.1):S16–S23.
14. Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344(8926):859–861
15. Pavlick KP, Laroux FS, Fuseler J, et al. (2002) Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33:311–322.
16. Babbs CF (1992) Oxygen radicals in ulcerative colitis. Free Radic Biol Med 13:169–181.
17. McKenzie SJ, Baker MS, Buffinton GD, et al. (1996) Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 98:136–141.
18. Seksik P, Rigottier-Gois L, Gramet G, et al. (2003) Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 52:237–242.
19. Mangin I, Bonnet R, Seksik P, et al. (2004) Molecular inventory of faecal microflora in patients with Crohn’s disease. FEMS Microbiol Ecology 50:25–36.
20. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633.
21. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. (1990) Clinical evidence supporting the radical scavenger mechanism of 5- aminosalicylic acid. Gastroenterology 98:1162–1169.
22. Millar AD, Rampton DS, Chander CL, et al. (1996) Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 39:407–415.
23. Rutgeerts P, Hiele M, Geboes K, et al. (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621.
24. Madden MV, McIntyre AS, Nicholls RJ (1994) Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 39:1193–1196.
25. Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole. A therapeutic review and update. Drugs 54:679–708.
26. Uzlikova M., Nohynkova E. The effect of metronidazole on the cell cycle and DNA in metronidazole-susceptible and -resistant Giardia cell lines. Mol. Biochem. Parasitol. 2014;198:75–81.
27. De Meo M., Vanelle P., Bernadini E., Laget M., Maldonado J., Jentzer O., Crozet M.P., Duménil G. Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest. Environ. Mol. Mutagen. 1992;19:167–181.
28. Tracy J.W., Webster L.T., Jr. Drugs used in the chemotherapy of protozoal infections: trypanosomiasis, leishmaniasis, amebiasis, giardiasis, trichomoniasis, and other protozoal infections. In: Hardman J.G., Limbird L.E., Molinoff P.B., Gilman A., editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. ninth ed. McGraw-Hill; New York: 1996. pp. 987–1008.
29. Akamatsu H., Oguchi M., Nishijima S., Takahashi M., Ushijima T., Niwa Y. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch. Dermatol. Res. 1990;282:449–454.
30. Andrioli N., Sabatini S.E., Mudry M.D., de Molina M.C.R. Oxidative damage and antioxidant response of Allium cepa meristematic and elongation cells exposed to metronidazole. Environ. Toxicol. Chem. 2012;31:968–972.
31. Yang S., Wang P., Yang X., Wei G., Zhang W., Shan L. A novel advanced oxidation process to degrade organic pollutants in wastewater: microwave-activated persulfate oxidation. J. Environ. Sci. 2009;21:1175–1180.
32. Narayanan S., Hünerbein A., Getie M., Jäckel A., Neubert R.H.H. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J. Pharm. Pharmacol. 2007;59:1125–1130.
33. Itälä E., Niskanen J., Pihlava L., Kukk E. Fragmentation patterns of radiosensitizers metronidazole and nimorazole upon valence ionization. J. Phys. Chem. A. 2020;124:5555–5562.
34. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol. 1998;37:263-266.
35. Boia S., Stratul S.T., Boariu M., Ursiniu S., Gotia S.L., Boia E.R., Borz C. Evaluation of antioxidant capacity and clinical assessment of patients with chronic periodontitis treated with nonsurgical periodontal therapy and adjunctive systemic antibiotherapy, Rom. J. Morphol. Embryol. 2018;59:1107–1113.
36. Kohanski M. A., Dwyer D. J., Wierzbowski J., Cottarel G., Collins J. J. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell. 2008;135(4):679–690.
37. Vatansever F., de Melo W. C., Avci P., et al. Antimicrobial strategies centered around reactive oxygen species – bactericidal antibiotics, photodynamic therapy, and beyond. FEMS Microbiology Reviews. 2013;37(6):955–989.
38. Cornejo-Garcia J. A., Mayorga C., Torres M. J., et al. Anti-oxidant enzyme activities and expression and oxidative damage in patients with non-immediate reactions to drugs. Clinical and Experimental Immunology. 2006;145(2):287–295.
39. Pélissier M. A., Marteau P., Pochart P. Antioxidant effects of metronidazole in colonic tissue. Digestive Diseases and Sciences. 2007;52(1):40–44.
40. Spolidorio L. C., Herrera B. S., Coimbra L. S., et al. The long-term administration of calcineurin inhibitors decreases antioxidant enzyme activity in the rat parotid and submandibular salivary glands. Life Sciences. 2015;134:1–8.
41. Kędzierska K., Sporniak-Tutak K., Bober J., et al. Oxidative stress indices in rats under immunosuppression. Transplantation Proceedings. 2011;43(10):3939–3945.